

BLOOD CANCER OXR – FINAL REPORT

Patient Information

Identification Data		General Biochemistry		Blood Drawn Realization	
HRN:	BRE00000273	Creatinine (mg/dL):	1.00	Blood Drawn Date:	<PII>
Name:	<PII> <PII>	ASAT (U/L):	8.00		
		ALAT (U/L):	<PII>	Urine Tumor Markers	
Personal Data		GGT (U/L):	7.00	<PII> (ng/mL):	11.10
Age (years):	23	Total Bilirubin (mg/dL):	1.00		
		Hemolized Sample:	No	Urine Drawn Realization	
Comorbidities				Urine Drawn Date:	<PII>
Atherosclerosis:	No	Serum Tumor Markers			
Chronic Liver Disease:	Yes	CA 15.3 (U/mL):	19.70	Lifestyle	
Diabetes Mellitus 1 or 2:	No	CEA (ng/mL):	1.60	Smoking:	Negative
Jaundice:	No	EGFR (ng/mL):	5.00		
Renal Failure:	Yes	NGAL (ng/mL):	4.60		
		NSE (ng/mL):	7.00		

Outcome

Results

Some Tumor Markers are outside the reference range and suggest malignancy.

“High”

Range: Low, Moderate, High

Comments

In absence of comorbidities that are well-known source of False <PII> (FP) in healthy patients by increasing some Tumor Markers levels, whole Tumor Markers levels suggest malignancy.

Conclusions

WE SUGGEST BLOOD CANCER. THE <PII> ICD-10-CM DIAGNOSIS CODE IS C50 (MALIGNANT NEOPLASM OF BLOOD).

This report has been generated from the data entered on <PII> 10:55:02 UTC/GMT.

Disclaimer

This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Blood Cancer has been developed for the exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm bears a Sensitivity = 82.3%, Specificity = 85.7%. Please note, negativity of the Tumor Markers does not exclude at 100% the possibility of a malignant epithelial tumor.